Targeting the Dynamics Between TAMs and CAR-T Cells in Solid Tumor Therapies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematological cancer treatment.
• Significant barriers persist in applying CAR T-cell therapy to solid tumors, primarily due to the immunosuppressive tumor microenvironment (TME).
• Tumor-associated macrophages (TAMs), particularly M2-like phenotypes, play a crucial role in establishing this immunosuppressive TME.

Purpose of the Study:

• To review the mechanisms by which M2-like TAMs suppress CAR T-cell function within the TME.
• To explore novel therapeutic strategies aimed at counteracting TAM-mediated immunosuppression.
• To re-evaluate the potential of CAR T-cell therapy in solid tumors by addressing these challenges.

Main Methods:

• Literature review focusing on the interactions between TAMs and CAR T-cells in solid tumors.
• Analysis of the molecular and cellular mechanisms underlying TAM immunosuppression.
• Identification and synthesis of emerging therapeutic approaches targeting TAMs.

Main Results:

• TAMs impair CAR T-cell effector functions through cytokine secretion, immune checkpoint upregulation, metabolic alterations, and post-translational modifications.
• Several novel strategies are being developed to target these TAM-mediated suppressive mechanisms.
• Overcoming TAM immunosuppression is critical for enhancing CAR T-cell efficacy in solid tumors.

Conclusions:

• TAMs represent a significant hurdle for CAR T-cell therapy in solid tumors.
• Targeting TAMs offers a promising avenue to improve CAR T-cell therapy outcomes.
• This review provides a framework for developing next-generation CAR T-cell therapies for solid malignancies.